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The development of tools for efficient targeting of antigens to antigen presenting cells is of great importance for vaccine
development. We have previously shown that fusion proteins containing antigens fused to the extra domain A from fibronectin
(EDA), an endogenous TLR4 ligand, which targets antigens to TLR4-expressing dendritic cells (DC), are highly immunogenic. To
facilitate the procedure of joining EDA to any antigen of choice, we have prepared the fusion protein EDAvidin by linking EDA to
the N terminus of streptavidin, allowing its conjugation with biotinylated antigens. We found that EDAvidin, as streptavidin, forms
tetramers and binds biotin or biotinylated proteins with a 𝐾𝑑 ∼ 2.6 × 10
−14mol/L. EDAvidin favours the uptake of biotinylated
green fluorescent protein by DC. Moreover, EDAvidin retains the proinflammatory properties of EDA, inducing NF-𝜅𝛽 by TLR4-
expressing cells, as well as the production of TNF-𝛼 by the human monocyte cell line THP1 and IL-12 by DC. More importantly,
immunization of mice with EDAvidin conjugated with the biotinylated nonstructural NS3 protein from hepatitis C virus induces
a strong anti-NS3 T cell immune response. These results open a new way to use the EDA-based delivery tool to target any antigen
of choice to DC for vaccination against infectious diseases and cancer.
1. Introduction
The development of prophylactic and therapeutic vaccines
requires strategies capable of stimulating CD8+ cytotoxic T
cells which recognize antigens expressed by infected cells
or tumors. The unique capacity of DC to present anti-
gens to T cells and elicit immune responses has prompted
their use in vaccination strategies. The “in vivo loading”
or “targeting” of antigens to DC through their surface
receptors [1–9] constitutes an alternative to the ex vivo
manipulation of dendritic cells (DC) for their transfer into
the patient (reviewed in [10]). It has been described that
the efficacy of antigen capture by DC dramatically affects
the immunogenicity of the antigen. But, the outcome of
the immune response induced by targeting antigens to DC
depends on the receptor used [3, 11–15]. Engagement of
TLR on DC loaded with the antigen induces DC activation,
expression of cytokines, and migration to draining lymph
nodes for an efficient presentation of the processed antigen
to T cells [16]. Recently, we have demonstrated that fusion
of an antigen to the extra domain A from fibronectin (EDA)
favours antigen targeting to TLR4-expressing DC, leading
to their maturation and enhancing cross-presentation and
immunogenicity of the antigen [4] as well as the induction of
antiviral/tumor immunity [17–19]. However, this vaccination
strategy requires the preparation of the corresponding fusion
protein between EDA and the selected antigen each time. In
order to facilitate the procedure of joining EDA to different
viral or tumoral antigens, we have taken the advantage of
the exceptionally high affinity of streptavidin for biotin, one
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of the strongest known noncovalent biological interactions
(𝐾𝑑 > 10
−15M) [20]. We hypothesised that a fusion protein
of EDA linked to streptavidin could be easily conjugated to
biotinylated antigens for their use as immunogens for vacci-
nation purposes. In this work, we found that EDAvidin was
able to tetramerize and bind to biotinylated proteins while
retaining the proinflammatory and DC targeting properties
of EDA. In addition, we found that EDAvidin conjugatedwith
the NS3 protein from hepatitis C virus (HCV) was able to
induce strong and specific T cell immune responses against
the main T cell epitopes from NS3 protein.
2. Material and Methods
2.1. Construction and Purification of the EDAvidin. The plas-
mid pET21a-Streptavidin-Alive [21] (Addgene, Cambridge,
MA) expressing wild-type subunit of streptavidin with a
6xHis tag was used for the construction of the expres-
sion plasmid pET21a-EDA-Streptavidin using conventional
cloning techniques. This plasmid expressing EDA in the C-
terminal end of streptavidin was verified by DNA sequenc-
ing and introduced into BL21(DE3). Recombinant protein
EDAvidin was purified from inclusion bodies by affinity
chromatography (Histrap, GE Healthcare, Uppsala, Sweden),
refolded in a sepharose G25 column using a urea gradi-
ent size-exclusion chromatography, dialysed, and removed
from endotoxins by using EndoTrap columns (Profos AG,
Regensburg, Germany) until endotoxin levels were below
0.2 EU/𝜇g protein (tested by quantitative chromogenic limu-
lus amebocyte lysate assay (Cambrex, Walkersville, MD,
USA)). Purified recombinant protein was analyzed by SDS-
PAGE and stained with Coomassie blue (Bio-Safe Coomassie
reagent, Bio-Rad, Hercules, CA, USA).
2.2. Binding Assay of EDAvidin to Biotinylated Proteins by
SDS-PAGE. The molecular weight marker containing
biotinylated proteins (MW 6,500–180,000, Sigma), or
the High-Range Rainbow Molecular Weight Marker
(12000–225000, GE Healthcare) as negative control, were
loaded into a 10% SDS-PAGE, transferred to nitrocellulose
membranes, and incubated with 1.33 nmol of EDAvidin or
EDA. After washing, membranes were incubated with a
rabbit polyclonal anti-EDA antibody (1/500) produced in
our laboratory. Membranes were then incubated with anti-
rabbit IgG horseradish-peroxidase (Cell Signaling) antibody
(1/2500) and developed using ECL chemiluminescence
system (Amersham). As a positive control, a membrane
was incubated with horseradish peroxidase conjugated
streptavidin (1/500) (GE Healthcare).
In some experiments, EDAvidin was incubated with
biotinylated proteins (i.e., OVA biot) and loaded into a 10%
SDS-PAGE to analyze the molecular size of the complexes
formed in comparison with the monomer OVA or the
EDAvidin tetramer alone. Gels were stained with Coomassie
blue (Bio-Safe Coomassie, Hercules, CA, USA).
2.3. ELISA-Based Binding Assays of EDAvidin to Biotinylated
Proteins. OVA protein (grade III), BSA (Sigma), or the
nonstructural NS3 protein from hepatitis C virus [19] were
biotinylated using sulfo-NHS-SS-Biotin (Thermo Scientific)
followingmanufacturer’s instruction.Microtiter plates (Nunc
MaxiSorp, Roskilde, Denmark) were coated with 0.1𝜇g/well
of biotinylated proteins in carbonate buffer 0.1M (pH 9,5).
Then, plates were incubated with PBS containing 10% FCS
(blocking buffer) during 1 h at room temperature. After
removing the blocking buffer, a 1/500 dilution of EDAvidin or
EDAproteinwas added and incubated at 37∘C for 90minutes,
washed, and incubated at 37∘C for 1 h with a 1/500 dilution of
a rabbit polyclonal anti-EDA antibody followed by a 1/2500
dilution of anti-rabbit whole IgGhorseradish peroxidase con-
jugated antibody (Sigma). Plates were developed by adding
100 𝜇L of TMB (BD Biosciences) and read at 450 nm using
the Multiskan Ascent (Thermo Electron Corporation).
2.4. Biomolecular Interaction Analysis. Binding capacity of
EDAvidin to biotinylated proteins was also analyzed by
surface plasmon resonance (SPR) using ProteOn XPR36
(Bio-Rad, Hercules, CA, USA) optical biosensor. OVA and
OVA-biotinylated proteins were covalently immobilized onto
the surface of a GLC sensor chips (Bio-Rad) using the cou-
pling reagents sulfo-NHS and EDC (Bio-Rad). After protein
immobilization, chip surface was treated with ethanolamine
to deactivate the excess of reactive esters. To determine
the equilibrium dissociation constant (𝐾𝑑) of EDAvidin to
biotinylated OVA protein, different concentrations of EDA-
vidin with 2-fold dilution of the maximum concentration
100 nM were injected in running buffer (PBS, 0.005% (v/v)
Tween 20, pH 7.4) over the coated sensor ships at a flow
rate of 30 𝜇L/min. Protein binding was evaluated during an
association phase (0–300 sec), which was followed by a dis-
sociation phase (injection of buffer only, 300–3700 sec). The
association phase, where EDAvidin protein is flowed across
the OVA biot coated sensor ship and binding is measured,
allows the determination of the rate of formation of the
complex over the time which is reflected by an increase in the
SPR response units (RUs). The kinetic of the increase in RU
determines the association constant (𝐾𝑎). In the dissociation
phase, the EDAvidin protein is removed from the flow, and
the rate of complex dissociation follows exponential decay
kinetics. This kinetic determines the dissociation constant
(𝐾𝑑). Data were double referenced by subtraction of control
flow cell (coated with nonbiotinylated OVA) and data from
Interspots, as recommended by themanufacturers. EDAvidin
affinity to OVA-biot and rate constants of the interaction
was determined by global analysis using Langmuir binding
model provided by the ProteOn X36 software (Bio-Rad).
After this process, the chip surface was regenerated by the
injection of free biotin (2 𝜇M), to remove the EDAvidin
coated protein to the chip. After this regeneration process,
different concentrations of streptavidin were injected in
running buffer at a flow of 30 𝜇L/min to determine the 𝐾𝑑
for streptavidin-biotin interaction.
2.5. Mice. Female C57BL/6 mice, 6–8 weeks old, from
Harlan (Barcelona, Spain) and HHD mice, transgenic for
human HLA-A2.1 and beta-2 microglobulin molecules [22],
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kindly provided by Dr. F. Lemonnier (Institute Pasteur, Paris,
France), were housed in appropriated animal care facilities
during the experimental period and handled following the
local and international guidelines required for experimenta-
tion with animals.
2.6. Targeting of Antigen to DC. To study the targeting capac-
ity of EDAvidin toDC, recombinant green fluorescent protein
(GFP) was biotinylated as described above and incubated for
15min with EDAvidin or with EDA. Resulting mixtures were
incubated with C57BL/6-derived bone-marrow-derived DC
(BMDC) [4] for 15min at 4∘C, washed, and analyzed by flow
cytometry. To study the capacity of EDAvidin to stimulate
the production of IL-12 by DC, BMDC were cultured at
37∘C and 5% CO2 with EDA or EDAvidin (500 nM), LPS
(0.1 𝜇g/mL), or culture medium. One day later, supernatants
were harvested to measure, and IL-12 (p70) by ELISA (BD-
Pharmingen), according to manufacturer’s instructions.
2.7. In Vitro Analysis on Monocyte Activation and Measure-
ment of Activation of TLR4 Signaling Pathway. THP-1 cells
(ATCC, Manassas, VA, USA) were grown as described [19],
plated at 2 × 105 cells/well, and cultured in the presence of
different concentrations of the indicated antigens. After 15
hours of incubation, culture supernatants were harvested
and human TNF-𝛼 released to the medium was quantified
using a commercial ELISA assay (BD-Pharmingen), accord-
ing to manufacturer’s instructions. To measure activation
of TLR4 signaling pathway, HEK293/hTLR4-MD2-CD14 or
HEK293/LacZ expressing cells were transfected with plas-
mid pNiFty-SEAP (Invivogen) carrying the human secreted
embryonic alkaline phosphatase gene (SEAP) controlled by
an NF-𝜅𝛽-inducible ELAM-1 promoter. Twenty-four hours
after transfection, cells were incubated in the presence or
absence of different concentrations of the indicatedmolecule.
After 24 hours, the expression of the reporter gene was
measured in culture supernatants by a colorimetric assay
(SEAP reporter assay kit, Invivogen). Results represent the
fold NF-𝜅𝛽 induction factor (OD obtained with supernatants
from HEK293/TLR4-MD2-CD14 divided by OD obtained
with supernatants from HEK293/LacZ).
2.8. In Vivo Induction of Anti-NS3 Immune Responses after
Immunization with EDAvidin Plus Biotinylated HCV-NS3
Protein. HHD mice [22] were immunized i.v. with 200𝜇L
of a saline solution containing (i) 2 nmol of EDAvidin plus
biotinylated NS3, (ii) 2 nmol of EDA-NS3, (iii) 2 nmol of
biotinylated NS3, (iv) 2 nmol of EDA plus 2 nmol of biotiny-
lated NS3, and (v) 2 nmol of streptavidin plus 2 nmol of
biotinylated NS3. Seven days after immunization, cytotoxic T
cell activity (CTL activity) was measured by an in vivo killing
assay. Briefly, naive splenocytes fromHHDmice were pulsed
with the HLA-A2-restricted peptide p1073 (CVNGVCWTV)
from NS3 (10 𝜇g/mL; 30 minutes, 37∘C), washed extensively,
and labeled with a high concentration (1.25𝜇M) of CFSE
(Invitrogen). The nonpulsed control population was labeled
with a low concentration (0.125 𝜇M) of CFSE. Both CFSEhigh-
and CFSElow-labeled cells were mixed at a 1 : 1 ratio (5 × 106
cells of each population) and then injected intravenously into
immunized mice. The number of CFSE+ cells remaining in
the spleen after 20 hours was determined by flow cytometry,
and the specific lysis was calculated as previously described
[23]. T cells producing IFN-𝛾 were enumerated by ELISPOT
using a kit from BD-Biosciences (San Diego, CA, USA)
according to manufacturer instructions, by culturing 8 × 105
splenocytes from immunized mice in the absence/presence
of peptide p1073 (10 𝜇g/mL), NS3 protein (0.1 𝜇g/mL), or
culture medium (negative control). The number of spots was
counted using an automated ELISPOT reader (CTL, Aalen,
Germany).
2.9. Statistical Analysis. Normality was assessed with
Shapiro-Wilk 𝑊 test. Statistical analyses were performed
using parametric (Student’s 𝑡-test and one-way ANOVA) and
nonparametric (Kruskal-Wallis and Mann-Whitney 𝑈) tests.
For all tests, a 𝑃 value < 0.05 was considered statistically
significant. Descriptive data for continuous variables are
reported as means ± SEM. Prism software (GraphPad
Software, Inc.) was used for statistical analysis.
3. Results
3.1. Recombinant EDAvidin Tetramerizes and Binds to Biotiny-
lated Proteins. Several reports have shown that the strong
affinity of avidin or streptavidin for biotin is dependent upon
the tetrameric architecture of the protein [24]. We produced
the recombinant protein EDAvidin by linking EDA to the
C-terminal end of streptavidin. SDS-PAGE analysis of the
purified protein showed a band corresponding to the putative
molecular weight of a tetramer form of EDAvidin (98 kDa)
(Figure 1(a)). When the sample was boiled before the SDS-
PAGE analysis, a band corresponding to the monomer
was observed (24.5 kDa), suggesting that the fusion protein
tetramerizes spontaneously in solution.
We studied by surface plasmon resonance the capacity
of EDAvidin to bind to the surface of a chip coated with
biotinylated OVA. Thus, by using different EDAvidin con-
centrations (100–6,5 nM), we found that EDAvidin bound
with high affinity to biotinylated OVA protein (Figure 1(b)).
When comparing this binding with that of streptavidin,
we observed that EDAvidin had a slightly lower affinity
(𝐾𝑑 ∼ 2.3 × 10
−14mol/L), although it is still in the range
of the very high affinity constant showed by streptavidin
(𝐾𝑑 > 10
−15mol/L).
Binding of EDAvidin to biotinylated proteins OVA (OVA
biot) or BSA (BSA biot) was also studied by ELISA. By incu-
bating OVA biot or BSA Biot-coated plates with EDAvidin or
with EDA (as control) and by quantification with anti-EDA
antibodies, it was found that EDAvidin, but not free EDA,
bound to biotinylated proteins (Figure 1(c)). The binding
capacity of EDAvidin to biotinylated proteinswas also studied
by SDS-PAGE. Thus, when EDAvidin was mixed with OVA
biot, the tetrameric EDAvidin was converted into a larger
molecular complex, corresponding to the putative EDAvidin-
OVA biot association (Figure 1(d)). Indeed, a band shift with
a retardation in the gel was observed for the tetrameric
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Figure 1: Recombinant EDAvidin tetramerizes and binds to biotinylated proteins. (a) SDS-PAGE of purified recombinant proteins stained
with Coomassie blue (1: (MWM: molecular weight marker); 2: denatured EDAvidin; 3: nondenatured EDAvidin). (b) Surface plasmon
resonance analysis of the capacity of EDAvidin and streptavidin to bind biotinylated proteins. Biotinylated ovalbumin was coated into the
chip, and EDAvidin or streptavidin were injected at different concentrations. The surface of the chip was regenerated by the injection of an
excess of 2𝜇M biotin before the injection of streptavidin (RU: surface plasmon resonance response units). (c) ELISA-based binding assays
of EDAvidin to biotinylated proteins. Biotinylated or nonbiotinylated ovalbumin (OVA) and bovine serum albumin (BSA) were coated into
the wells of ELISA plates. EDAvidin or EDA alone was added to the wells and after extensive washes, the plates were developed using rabbit
polyclonal anti-EDA antibodies. (d) Binding assay of EDAvidin to biotinylated proteins by SDS-PAGEas 1: EDAvidin in its tetrameric form;
2: biotinylated OVA; 3: EDAvidin plus biotinylated OVA; 5: (MWM).
EDAvidin (lane 1) or for the free OVA biot (lane 2) when
both proteins were combined (lane 3). Although we have
not done the stoichiometric analysis, the larger molecular
complex found in lane 3 should correspond to the putative
molecular weight of 3 or 4 molecules of bOVA combined
with the tetrameric EDAvidin. Binding of EDAvidin to
biotinylated proteins was also studied by Western-blot using
anti-EDA antibodies to detect a molecular weight marker
mixture consisting in biotinylated proteins. It was found
that only EDAvidin bounds to the biotinylated proteins
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(See Supplementary Figure 1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2013/864720).
3.2. EDAvidin Retains the Proinflammatory Activity of EDA
and Targets Biotinylated Antigens to DC. In previous works,
we found that recombinant EDA bound to TLR4 and acti-
vated its downstream signaling pathway [4, 19]. To study the
capacity of EDAvidin to target an antigen to DC, biotiny-
lated green fluorescent protein (GFP-biot) was mixed with
EDAvidin and added to BMDC. After 15min of incubation,
cells were washed, and GFP uptake by DC was analyzed by
flow cytometry. It was found that a significant proportion
of BMDC incubated with EDAvidin + GFP-biot was highly
labeled with the fluorescent protein (Figure 2(a)). This result
was not foundwhen BMDCwere incubatedwith biotinylated
GFP alone or in combination with EDA, suggesting that
EDAvidin was targeting the biotinylated protein to DC.
EDA activates TLR4 signaling pathway and induces DC
maturation and the production of proinflammatory cytokines
by activated cells [4]. We thus first analyzed EDAvidin-
induced TLR4 signaling, measured as translocation of NF-
𝜅𝛽. By using HEK TLR4 or HEKLacZ cells transfected with
a plasmid carrying the human secreted embryonic alkaline
phosphatase gene, under the control of the NF-𝜅𝛽-inducible
ELAM-1 promoter, we observed that EDAvidin, although less
efficient than EDA, activated the TLR4 signaling pathway
(Figure 2(b)).
We next studied the proinflammatory activity of EDA-
vidin by measuring its capacity to induce the production
of cytokines in two different systems: TNF-𝛼 by the TLR4+
human monocytic cell line THP1 and IL-12 by murine
BMDC. In both cases, we observed that EDAvidin, although
less efficient than free EDA, induced the production of the
corresponding cytokine (Figures 2(c) and 2(d)).
3.3. EDAvidin Plus Biotinylated NS3 Induces Strong Anti-
NS3 Cellular Immune Responses In Vivo. We had shown that
the fusion protein EDA-NS3, containing NS3 protein from
hepatitis C virus, induced strong cellular immune responses
specific for NS3 when used as immunogen [19].Therefore, we
sought to analyze its immunogenic properties in vivo when
administered with a biotinylated antigen. As with previous
biotinylated proteins, we first demonstrated that biotinylated
NS3 (NS3Biot) coated in an ELISA plate is associated with
EDAvidin, but not with free EDA (Figure 3(a)). We then
tested in vivo the immunogenicity of a mixture of EDA-
vidin plus NS3Biot by immunizing HHD transgenic mice.
Its immunogenicity was compared with equivalent molar
amounts (2 nmol) of EDA-NS3, EDA plus NS3Biot, NS3Biot
or streptavidin plus NS3Biot. One week after immunization,
mice were sacrificed and spleen cells were cultured in the
presence of the NS3 HLA-A2-restricted CD8 epitope p1073
or with recombinant NS3 protein to measure the number
of IFN-𝛾 producing cells by ELISPOT. This experiment
showed that EDAvidin plus NS3biot was as good as EDA-NS3
protein to induce anti-NS3 specific T cell immune responses,
whereas NS3biot alone or mixed with streptavidin or with
free EDA barely induced any response (Figure 3(b)). Similar
results were obtained when analyzing T cell responses in
in vivo killing assays, which measured the capacity of these
immunogens to induce cytotoxic T cells able to kill target cells
pulsed with peptide p1073 (Figure 3(c)).
4. Discussion
Over the last decades, several vaccine strategies enabling
delivery of Ags for presentation by APC have been assayed
with varying degrees of success [3, 11–15, 25–28]. Since
maturation of the DC is essential to trigger adaptive immune
responses [29], procedures that simultaneously target the
antigen to DC and induce their maturation could lead
to the development of a new generation of vaccines that
might work in synergy with mild and safe adjuvants. We
have previously reported that fusion of an antigen with
EDA leads to antigen targeting to TLR4-expressing DC,
enhancing cross-presentation and immunogenicity [4]. Here,
we describe a novel antigen delivery approach in which a
biotinylated antigen is bound noncovalently to EDAvidin
protein, a construct which retains the TLR4 targeting ability
and inflammatory properties of EDA. This would allow the
combination of the tetrameric EDAvidin with a broad range
of commercially available antigens or adjuvants which can
be easily biotinylated, facilitating the preparation of DC-
targeted antigens to be used as immunogens for the induction
of T cell responses.
By using different approaches, we have shown that EDA-
vidin forms tetrameric complexes and binds to biotinylated
antigens with a very high affinity (𝐾𝑑 ∼ 2.3 × 10
−14mol/L).
Importantly, EDAvidin greatly increased biotinylated GFP
uptake by DC and retained EDA proinflammatory capacity.
It induced NF-𝜅𝛽 activation, an important mediator for DC
maturation [30, 31] and stimulated the production of TNF-𝛼
by THP1 cells as well as the production of IL-12 by murine
BMDC. The final aim when designing EDAvidin was to
facilitate conjugation of EDA to biotinylated antigens to be
used as vaccines. Thus, we compared the immunogenicity of
EDAvidin plus NS3biot with that of a fusion protein between
EDA and HCV NS3, an immunogen known to induce a
specific T cell response when administered in the absence
of additional adjuvants [19]. We first found that EDAvidin
interacted physically with NS3biot. But more importantly,
we found that immunization with a mixture of EDAvidin
and NS3biot induced a T cell immune response against NS3
similar to that obtained when using EDA-NS3 fusion protein.
It is interesting to note that either when NS3 is not linked
to the antigen delivery system (e.g., by using EDA instead
of EDAvidin), or when tetrameric complexes do not retain
the proinflammatory properties of EDA (e.g., when using
streptavidin instead of EDAvidin), the immunogens show
a much lower efficacy, demonstrating that both EDAvidin
properties, antigen targeting, and DC activation are essential
for efficient priming of T cells responses.
Multivalency of streptavidin and EDAvidin might be
considered as an advantage for some applications. The
tetrameric structure of EDAvidin might allow the combina-
tion of different biotinylated antigens or adjuvants within
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Figure 2: EDAvidin targets biotinylated antigens to DC and retains the proinflammatory activity of EDA. (a) Flow cytometric analysis of
BMDC incubatedwith the indicated proteins. (b) Colorimetric assay tomeasureNF-𝜅𝛽 induction inHEKTLR4 orHEKLacZ expressing cells
in response to different concentrations of EDA, EDAvidin, LPS, or culturemedium (Neg). Results represent the NF-𝜅𝛽 fold induction. (c)The
humanmonocytic cell line THP1 was incubated in the absence or presence of the indicated concentrations of EDAvidin, EDA, LPS, or culture
medium (Neg). After 15 hours of culture, supernatants were harvested and the released TNF-𝛼 was measured by ELISA. (d) Production of
IL-12 by BMDC after incubation with 500 nM EDA, 500 nM EDAvidin, 0.1 𝜇g/mL LPS or culture medium (Neg). Twenty-four hours later,
culture supernatant was harvested and IL-12 released to the medium was measured by ELISA. All data are representative of two independent
experiments.
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Figure 3: EDAvidin binds to biotinylated NS3 and induces strong anti-NS3 cellular immune responses in vivo. (a) ELISA-based binding
assays of EDAvidin to biotinylated NS3. Biotinylated or nonbiotinylated NS3 were coated into the wells of ELISA plates. EDAvidin or EDA
alone was added to the wells and after extensive washes, the plates were developed using rabbit polyclonal anti-EDA antibodies. ((b), (c)) In
vivo induction of anti-NS3 T cell responses. HHD transgenic mice were immunized i.v. with NS3Biot, EDA plus NS3Biot, streptavidin plus
NS3Biot, EDA-NS3, or with EDAvidin plus NS3Biot in saline. Seven days after immunization, anti-NS3 immune response was analyzed by
measuring the number of IFN-𝛾 producing cells by ELISPOT in response to the T cell epitope p1073, NS3 protein, or culture medium (Neg)
(b) or by in vivo killing (c) as described in methods.
a single targeting vector. This would favour both sides
required for antigen presentation, simultaneous targeting,
and therefore induction of immune responses against several
antigens, as well as the inclusion of new biotinylated adju-
vants which would collaborate with EDA in APC activation
[17–19], a situation that has been demonstrated to improve
phagosome maturation and antigen presentation by APC
[32].
Proteins can be biotinylated chemically or enzymati-
cally using already established protocols. Using our strategy,
we could also consider the possibility to biotinylate more
complex antigenic structures such as whole cells for their
engineering to codisplay immunomodulatorymolecules, as it
has been described previously with a different approach [33].
EDAvidin could also be used to decorate a biotinylated tumor
cell to render it more immunogenic allowing its capture
by TLR4 expressing DC. Future experiments need to be
conducted to explore this possibility.
In summary, we have found that a chimeric protein con-
taining EDA fused to the N terminus of streptavidin retains
functional properties of EDA and facilitates its conjugation to
any antigen of choice and results in a new tool which opens
a new way to use this antigen delivery system in vaccination
against infectious diseases and cancer.
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